KIT and cancer: Chung et al. [118] observed a significant inhibition of the viability and proliferation of cancer stem-like cells (OVCAR3 and OVCAR3 CD44+ CD117+ cells) via paclitaxel combined with salinomycin in a dose-dependent manner.